Zydus Cadila gets tentative USFDA nod for anti-cancer drug

Last Updated on October 17, 2024 by The Health Master

Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules.

Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Palbociclib Capsules in the strengths of 75 mg, 100 mg, and 125 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.

Aslso read: Sun Pharma launches ILUMYA – Tildrakizumab

Palbociclib is an anti-cancer medicine that interferes with the growth and spread of cancer cells in the body. The company said the newly approved medication will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 302 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04. Shares of Cadila Healthcare were trading 1.07 per cent lower at Rs 379.80 on BSE.

• Key Notes on Revised Schedule M: Point No. 11 – Personnel
• USFDA issued Form 483 with two observations to Aurobindo for API plant
• NPPA fixed retail price of 65 formulations: December 2024
• Key Notes on Revised Schedule M: Point No. 10 – Self Inspection
• Medical Device recall: USFDA classifies recall of these catheters as ‘most serious’
• NPPA: New Strategy to Curb Drug Price Hikes

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.